漱玉平民大药房连锁股份有限公司 董事会提名委员会制度 第一章 总 则 第一条 为规范公司领导人员的产生，优化董事会组成，完善公司治理结 构，根据《中华人民共和国公司法》（以下简称《公司法》）、《上市公司治 理准则》、《漱玉平民大药房连锁股份有限公司章程》（以下简称《公司章 程》）及其他有关规定，漱玉平民大药房连锁股份有限公司（以下简称"本公 司"或"公司"）特设立董事会提名委员会,并制定本制度。 第二条 董事会提名委员会是董事会设立的专门工作机构,主要负责对公司 董事和高级管理人员的人选、选择标准和程序进行选择并提出建议。 第二章 人员组成 第三条 提名委员会成员由三名董事组成，其中两名由独立董事担任。 第四条 提名委员会委员由董事长、二分之一以上独立董事或者全体董事 的三分之一提名,并由董事会选举产生。 第五条 提名委员会设主任委员（召集人）一名，由独立董事委员担任， 负责主持委员会工作；主任委员在委员内选举，并报请董事会批准产生。 第六条 提名委员会任期与董事会任期一致，委员任期届满，连选可以连 任。期间如有委员不再担任公司董事职务，自动失去委员资格，并由委员会根 据上述第三至第五条规定补足委员人数。 第 ...

| 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2024-040 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司（以下简称"公司"）于 2024 年 4 月 25 日召开第 三届董事会第二十八次会议审议通过了《关于调整第三届董事会审计委员会委员的议案》， 现将相关情况公告如下： 根据中国证券监督管理委员会颁布的《上市公司独立董事管理办法》第五条规定："审 计委员会成员应当为不在上市公司担任高级管理人员的董事"。为进一步完善公司治理结构， 结合公司实际情况，公司董事会对第三届董事会审计委员会部分委员进行调整，董事、副总 裁、董事会秘书李强先生不再担任第三届董事会审计委员会委员职务。为保障审计委员会 规范运作，公司董事会推举董事长李文杰先生担任审计委员会委员，与独立董事晏莉女士、 李相杰先生共同组成第三届董事会审计委员会，任期自本次董事会审议通过之日起至本届 董事会期限届满之日止。 公司董事会审计委员会其他委员保持不变，本次调整前后公司董事会审计委员会成员 情况如下： 调整前：晏莉女士（主任委员）、李相杰先生 ...

漱玉平民大药房连锁股份有限公司 内部审计制度 第一章 总 则 第一条 为规范漱玉平民大药房连锁股份有限公司（以下简称"公司"）内 部审计工作，提高内部审计工作质量，保护投资者合法权益，防范和控制公司经 营风险，依据《中华人民共和国审计法》《审计署关于内部审计工作的规定》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》及 《漱玉平民大药房连锁股份有限公司章程》（以下简称《公司章程》）等的有关 规定，结合公司实际情况，制定本制度。 第二条 本制度所称内部审计，是指由公司内部审计部门依据国家有关法 律、行政法规和规范性文件以及《公司章程》和本制度的规定，按照一定的程序 和方法，对公司内部机构、控股子公司以及具有重大影响的参股公司的内部控制 和风险管理的有效性、财务信息的真实性和完整性以及经营活动的效率和效果等 开展的一种评价活动。 第三条 本制度所称内部控制，是指公司董事会、监事会、高级管理人员及 其他有关人员为实现下列目标而提供合理保证的过程： （三）保障公司资产的安全； （四）确保公司信息披露的真实、准确、完整和公平。 第二章 内部审计机构和人员 第四条 公司在董事会审计委员会下设立 ...

漱玉平民大药房连锁股份有限公司 2023 年度独立董事述职报告 各位股东及股东代表： 本人晏莉作为漱玉平民大药房连锁股份有限公司（以下简称"公司"）独 立董事，在 2023 年度严格按照《中华人民共和国公司法》（以下简称"《公 司法》"）《上市公司独立董事管理办法》《上市公司治理准则》等法律法 规、规范性文件以及《漱玉平民大药房连锁股份有限公司章程》（以下简称 "《公司章程》"）的规定和要求，认真、勤勉、独立的履行职责，积极出 席相关会议，认真审议董事会各项议案，充分发挥了独立董事及各专门委员 会委员的作用，切实维护了公司和全体股东的利益。现将本人 2023 年度履 行独立董事职责情况汇报如下： 一、基本情况 本人晏莉，中国籍，无境外居留权，1965 年生，大学本科学历，会计学专业， 注册会计师。2011 年 11 月至 2020 年 4 月，任天健会计师事务所（特殊普通合 伙）山东分所合伙人；2020 年 5 月至 2022 年 7 月，任天健会计师事务所（特殊 普通合伙）山东分所顾问；2022 年 8 月至 2024 年 3 月，任中诚华企业管理咨询 （山东）有限公司执行董事兼总经理；2022 年 10 ...

Financial Performance - The company's operating revenue for 2023 was approximately ¥9.19 billion, representing a 17.49% increase compared to ¥7.82 billion in 2022[22]. - The net profit attributable to shareholders decreased by 42.01% to ¥133.06 million from ¥229.43 million in the previous year[22]. - The net profit after deducting non-recurring gains and losses also fell by 42.34% to ¥126.88 million from ¥220.04 million in 2022[22]. - The basic earnings per share dropped to ¥0.33, a decrease of 42.11% from ¥0.57 in the previous year[22]. - The total assets of the company increased by 18.70% to approximately ¥9.33 billion compared to ¥7.86 billion at the end of 2022[22]. - The net assets attributable to shareholders rose by 2.72% to approximately ¥2.29 billion from ¥2.23 billion in 2022[22]. - The net cash flow from operating activities was approximately ¥142.91 million, a decrease of 3.73% from ¥148.44 million in the previous year[22]. - The weighted average return on net assets decreased to 6.28%, down from 11.55% in 2022, reflecting a decline of 5.27%[22]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of ¥0.5 per 10 shares to all shareholders, with no bonus shares issued[4]. - The profit distribution plan for 2023 proposed a cash dividend of 0.5 CNY per 10 shares (including tax), with a total cash dividend payout of 46,614,100.00 CNY[184]. - The company maintained a cash dividend policy with a clear distribution standard and procedure, ensuring the protection of shareholders' interests[185]. - The company did not issue any bonus shares or increase capital from the capital reserve during the profit distribution[184]. Market Position and Growth - The retail market for pharmaceuticals in China reached CNY 501.5 billion in 2023, with a year-on-year growth of 3.3%[35]. - E-commerce B2C sales in the pharmaceutical sector grew by 21.0%, significantly outpacing the growth of physical stores[35]. - The company ranked 8th in the "Top 50 Chain Pharmacies" in China for 2022-2023, reflecting its strong market position[36]. - The overall retail sales of consumer goods in China increased by 7.2% in 2023, indicating a positive market trend for the pharmaceutical retail sector[34]. - The company opened 1,881 new stores in 2023, bringing the total number of stores to 7,337, with 4,104 being directly operated stores[41]. Operational Efficiency and Strategy - The company has adopted a combined procurement model to enhance operational efficiency and meet regional demands[37]. - The company has implemented a digital transformation strategy, launching a new ERP system and a spatial data site selection platform, which has improved operational efficiency and new store expansion capabilities[57]. - The company aims to deepen its market presence in northern regions while maintaining a focus on the Shandong market, utilizing a combination of self-operated, franchised, and acquired stores for expansion[64]. - The company is adopting a "new store opening + acquisition + cooperation + franchising" strategy to accelerate store network expansion and strengthen market barriers in existing regions[124]. Investments and Acquisitions - The company has made significant investments in health equipment and rehabilitation products, targeting the aging population with tailored services[67]. - The company has acquired several pharmacy chains, including a 69% stake in Harbin Baofeng Pharmacy, to expand its market presence[75]. - The company completed significant equity investments totaling CNY 476,451,944.28 during the reporting period[99]. - The company has completed the acquisition of 90% control in Huai'an Xiansheng Pharmaceutical Management Co., Ltd. and 51% control in Gansu Shuyuan Baixing Pharmaceutical Chain Co., Ltd.[198]. Employee and Talent Management - The total number of employees at the end of the reporting period is 16,485, with 4,818 in the parent company and 11,667 in major subsidiaries[178]. - The company plans to implement an employee stock ownership plan to enhance the interest-sharing mechanism between workers and owners, improving governance and competitiveness[180]. - The company emphasizes a diversified incentive mechanism, including individual, team, and organizational incentives, to enhance talent value contribution[179]. - The company is committed to talent development through its training academy, which has nearly 500 instructors, ensuring a steady supply of qualified professionals to support its growth[127]. Risk Management and Governance - The company has set up a risk control center to enhance its comprehensive risk management system, focusing on identifying, measuring, monitoring, and addressing risks[121]. - The company is actively monitoring industry policy changes to adapt its business model and ensure compliance with regulations, thereby mitigating operational risks[123]. - The company has established a comprehensive internal management and control system, ensuring independence from controlling shareholders[147]. - The company has implemented a structured internal control framework to ensure compliance and operational efficiency[197]. Future Outlook - The company plans to focus on high-quality development in 2024, emphasizing customer value and digital transformation to improve operational efficiency[117]. - The strategy includes expanding through self-built stores, acquisitions, and partnerships, aiming for steady growth while deepening regional presence[117]. - The company aims to develop a comprehensive health ecosystem, leveraging its pharmaceutical retail business to create a leading smart health service platform[117]. - The company plans to enhance customer value by developing differentiated products and providing comprehensive health solutions, while actively managing membership services to identify growth opportunities[120].

漱玉平民大药房连锁股份有限公司 章 程 1 | | 录 | | --- | --- | | 目 | | | 第一章 | 总则 3 | | --- | --- | | 第二章 | 经营宗旨和范围 4 | | 第三章 | 股份 4 | | 第一节 | 股份发行 4 | | 第二节 | 股份增减和回购 5 | | 第三节 | 股份转让 6 | | 第四章 | 股东和股东大会 7 | | 第一节 | 股东 7 | | 第二节 | 股东大会的一般规定 9 | | 第三节 | 股东大会的召集 13 | | 第四节 | 股东大会的提案与通知 14 | | 第五节 | 股东大会的召开 15 | | 第六节 | 股东大会的表决和决议 18 | | 第五章 | 董事会 22 | | 第一节 | 董事 22 | | 第二节 | 董事会 24 | | 第六章 | 总裁及其他高级管理人员 28 | | 第七章 | 监事会 30 | | 第一节 | 监事 30 | | 第二节 | 监事会 30 | | 第八章 | 财务会计制度、利润分配和审计 32 | | 第一节 | 财务会计制度 32 | | 第二节 | 内部审计 35 | | 第三 ...

漱玉平民大药房连锁股份有限公司 2023 年度独立董事述职报告 各位股东及股东代表： 本人李相杰作为漱玉平民大药房连锁股份有限公司（以下简称"公司"） 独立董事，在 2023 年度严格按照《中华人民共和国公司法》（以下简称"《公 司法》"）《上市公司独立董事管理办法》《上市公司治理准则》等法律法 规、规范性文件以及《漱玉平民大药房连锁股份有限公司章程》（以下简称 "《公司章程》"）的规定和要求，认真、勤勉、独立的履行职责，积极出 席相关会议，认真审议董事会各项议案，充分发挥了独立董事及各专门委员 会委员的作用，切实维护了公司和全体股东的利益。现将本人 2023 年度履 行独立董事职责情况汇报如下： 一、基本情况 本人李相杰，中国籍，无境外居留权，1967 年生，硕士研究生学历，法学专 业。1993 年 3 月至 2000 年 2 月，任山东纵横家律师事务所合伙人；2000 年 3 月 至 2000 年 12 月，任北京广盛律师事务所专职律师；2001 年 1 月至 2008 年 10 月，任山东舜天律师事务所合伙人；2008 年 11 月至今，任山东誉实律师事务所 主任；2013 年 5 月至 2019 年 ...

Financial Performance - The company's revenue for Q1 2024 was ¥2,439,083,820.11, representing a 17.69% increase compared to ¥2,072,482,825.34 in the same period last year[4] - Net profit attributable to shareholders decreased by 83.72% to ¥10,508,208.55 from ¥64,553,649.73 year-on-year[4] - Basic and diluted earnings per share fell by 81.25% to ¥0.03, down from ¥0.16 in the same period last year[4] - The company achieved operating revenue of CNY 243.91 million in Q1 2024, representing a year-on-year increase of 17.69%[16] - The net profit attributable to shareholders decreased by 83.72% to CNY 10.51 million compared to the same period last year[16] - The net profit after deducting non-recurring gains and losses fell by 84.25% to CNY 9.51 million year-on-year[16] - Net profit for Q1 2024 was ¥11,377,582.93, a decrease of 82.9% from ¥66,526,141.25 in Q1 2023[30] - Earnings per share for Q1 2024 were ¥0.03, down from ¥0.16 in the same quarter last year[31] Cash Flow and Assets - The net cash flow from operating activities increased by 32.89% to ¥75,184,147.94, up from ¥56,575,234.08 in the previous year[4] - Cash received from operating activities totaled CNY 2,701,517,754.85, compared to CNY 2,216,545,326.15 in Q1 2023, reflecting a year-over-year increase of approximately 21.9%[34] - Total current assets amounted to approximately 5.71 billion CNY, an increase from 5.51 billion CNY at the beginning of the period[25] - Total assets reached approximately 9.56 billion CNY, up from 9.33 billion CNY at the beginning of the period[25] - Total cash and cash equivalents at the end of Q1 2024 amounted to CNY 946,508,791.12, up from CNY 1,021,875,903.46 at the end of Q1 2023[35] Liabilities and Equity - Total liabilities increased to ¥7,200,124,190.48 in Q1 2024 from ¥6,967,443,876.48 in Q1 2023[27] - Total equity attributable to shareholders of the parent company decreased to ¥2,268,028,613.50 from ¥2,292,063,021.84 year-over-year[27] - Minority interests increased to ¥96,617,961.98 in Q1 2024 from ¥74,169,508.13 in Q1 2023[27] - Long-term borrowings increased to approximately 749.83 million CNY from 658.18 million CNY[26] Operational Changes - The company plans to expand its logistics capabilities, which contributed to increased operational costs impacting net profit[9] - The company operates a total of 7,934 stores across several provinces, with 4,341 being direct-operated stores[17] - The company opened 22 new stores and closed 3 stores in Q1 2024, resulting in a net increase of 19 stores[18] - The company is focusing on a direct chain marketing model and steady expansion strategy in various provinces[17] Expenses and Margins - The gross margin decreased by 1.7 percentage points due to changes in healthcare policies affecting sales channels and product selection[16] - The company reported a significant increase in sales expenses, which rose to ¥523,927,303.51 from ¥424,345,254.99 in the previous year[30] - The company experienced a rise in management expenses, totaling ¥73,724,503.68 compared to ¥61,463,906.19 in the same period last year[30] Shareholder Actions - The top shareholder, Li Wenjie, holds 35.17% of the shares, with a total of 142,560,000 shares pledged[12] - The company plans to optimize product structure and enhance service quality to improve profitability amid market challenges[16] - The company has a total of 296,040,000 restricted shares, with specific release dates for certain shareholders[15] - The company approved a second batch of restricted stock grants on February 7, 2024, awarding 605,000 shares at a price of 8.675 CNY per share to 32 incentive recipients[19] - The company plans to repurchase shares with a total fund of no less than 40 million CNY and no more than 60 million CNY, with a maximum repurchase price of 18 CNY per share[20] - As of March 31, 2024, the company has repurchased a total of 2,602,588 shares, accounting for 0.64% of the total share capital, with a total transaction amount of approximately 38.12 million CNY[20] Investment Activities - Total cash inflow from investment activities was CNY 152,897,493.80, significantly higher than CNY 7,890,915.99 in the previous year[35] - The company reported a total cash outflow from investment activities of CNY 133,783,524.18, a decrease from CNY 270,591,408.28 in the previous year[35] - The company received CNY 3,150,000.00 from investments in Q1 2024, compared to CNY 1,664,000.00 in the previous year, indicating growth in investment activities[35] Debt and Financing - The company reported a significant increase in long-term payables by 4891.99% to ¥18,795,889.65, primarily due to financing leases[9] - The net cash flow from financing activities for Q1 2024 was CNY 22,304,637.52, compared to a negative cash flow of CNY -282,889,970.43 in Q1 2023, indicating a recovery in financing[35] - The cash flow from financing activities included CNY 358,540,000.00 received from borrowings, a significant increase from CNY 50,000,000.00 in Q1 2023[35] Inventory and Impairment - The company experienced a 327.50% increase in asset impairment losses, amounting to -¥7,969,615.48, due to increased inventory[9] - The company reported a significant increase in inventory, with current inventory valued at approximately 2.16 billion CNY, compared to 2.07 billion CNY at the beginning of the period[24]

漱玉平民大药房连锁股份有限公司 董事会薪酬与考核委员会制度 第一章 总 则 第一条 为进一步建立健全公司董事（非独立董事）及高级管理人员的考核 和薪酬管理制度，完善公司治理结构，根据《中华人民共和国公司法》（以下简 称"《公司法》"）《上市公司治理准则》《漱玉平民大药房连锁股份有限公司 章程》（以下简称"《公司章程》"）及其他有关法律法规、规范性文件等规定， 公司董事会特设立薪酬与考核委员会（以下简称"委员会"），并制定本制度。 第二条 薪酬与考核委员会是董事会设立的专门工作机构，主要负责制定 公司董事及高级管理人员的考核标准并进行考核；负责制定、审查公司董事高级 管理人员的薪酬政策与方案，对董事会负责。 第三条 本制度所称董事是指在公司支取薪酬的董事长、董事（非独立董 事），高级管理人员是指董事会聘任的总裁、副总裁、财务总监、董事会秘书以 及由总裁提请董事会认定的其他高级管理人员。 第二章 人员组成 第四条 委员会成员由三名董事组成，其中两名由独立董事担任。 第五条 委员会由董事长、二分之一以上独立董事或者全体董事的三分之 一提名，并由董事会选举产生。 （二）制定或者变更股权激励计划、员工持股计划，激励对象 ...

东兴证券股份有限公司关于漱玉平民大药房连锁股份有限公 司 2023 年度募集资金存放与使用情况的核查意见 东兴证券股份有限公司（以下简称"东兴证券"或"保荐机构"）作为漱玉平 民大药房连锁股份有限公司（以下简称"漱玉平民"或"公司"）持续督导阶段的 保荐机构，根据《证券发行上市保荐业务管理办法》《上市公司监管指引第 2 号— —上市公司募集资金管理和使用的监管要求》《深圳证券交易所创业板股票上市规 则》以及《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》等相关法律、法规和规范性文件的规定，对漱玉平民 2023 年度募集资金 存放与使用情况进行了专项核查，核查意见如下： 一、募集资金基本情况 （一）募集资金到位情况 1、首次公开发行股票 经中国证券监督管理委员会《关于同意漱玉平民大药房连锁股份有限公司首 次公开发行股票注册的批复》（证监许可[2021]1808 号）同意注册，公司首次公开 发行人民币普通股（A 股）4,054.00 万股，每股面值人民币 1.00 元，每股发行价 格为人民币 8.86 元，发行募集资金总额为人民币 359,184,400.00 元，扣除发行费 用人民币 ...